New imaging agent could spot hidden heart disease

NCT ID NCT06790394

Recruiting now Diagnosis Sponsor: Lantheus Germany GmbH Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 04, 2026 · Updated 3 times

Summary

This study tests whether a radioactive tracer called Florbetaben F18 can reliably detect amyloid deposits in the heart using PET scans. Researchers will scan 15 people with and without cardiac amyloidosis twice to see if the results are consistent. The goal is to improve diagnosis of this serious heart condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Florbetaben F18 (a radioactive tracer used in PET scans)
What this could lead to: If successful, this could lead to a more reliable and non-invasive way to diagnose cardiac amyloidosis, helping doctors detect the disease earlier.
What could go wrong: This is a very early (Phase 1) study with only 15 participants, so results may not apply to everyone. The tracer is for imaging only and does not treat the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AL CARDIAC AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis Amyloid Neuropathies, Familial amyloidosis wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC AMYLOIDOSIS

Contacts and locations

Locations

King's College London
COMPLETED

London, SE1 7EH, United Kingdom
Royal Free Hospital
RECRUITING

London, NW3 2QG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.